IκBε缺陷加速慢性淋巴细胞白血病疾病进展
NFKBIE基因编码NF-κB抑制蛋白IκBε,在3-7%的慢性淋巴细胞白血病(CLL)患者中发生突变,最常见为4-bp移码缺失,与白血病B细胞NF-κB激活及不良临床结局相关。研究者通过体外和体内稳定下调NFKBIE表达,发现IκBε缺失导致NF-κB通路激活,以剂量依赖方式促进CLL细胞迁移和增殖,并足以诱导淋巴器官中CLL克隆更快扩增,在异种移植和基因修饰小鼠中均导致侵袭性疾病和生存期缩短。IκBε缺陷还伴随MAPK通路改变(在NFKBIE突变患者样本的RNA测序中亦得到证实)及对BTK抑制剂伊布替尼的耐药。
要点
- NFKBIE在3-7%的CLL患者中突变,最常见为4-bp移码缺失,与NF-κB激活和不良临床结局相关。
- IκBε缺失以剂量依赖方式激活NF-κB通路,促进CLL细胞迁移和增殖。
- NFKBIE失活足以加速淋巴器官中CLL克隆扩增,在异种移植和基因修饰小鼠中导致侵袭性疾病和生存期缩短。
核心结论
- IκBε缺失通过激活NF-κB通路及改变MAPK通路,加速CLL克隆扩增并导致侵袭性疾病和生存期缩短,且与伊布替尼耐药相关。
- 作者指出本研究凸显NF-κB通路在CLL中的多层面相关性,并为将这些发现转化为新的治疗选择铺平道路。
研究设计与样本
- 体外和体内研究:工程化CLL B细胞和CLL倾向小鼠以稳定下调NFKBIE表达,研究其在调控NF-κB活性和疾病扩增中的作用。
- 使用异种移植和基因修饰小鼠模型。
- 对NFKBIE突变患者样本进行RNA测序。
主要发现
- IκBε缺失导致NF-κB通路激活,并以剂量依赖方式促进CLL细胞迁移和增殖。
- NFKBIE失活足以诱导淋巴器官中CLL克隆更快速扩增,在异种移植和基因修饰小鼠中均导致侵袭性疾病和生存期缩短。
- IκBε缺陷与MAPK通路改变相关,并在NFKBIE突变患者样本的RNA测序中得到证实。
- IκBε缺陷与对BTK抑制剂伊布替尼的耐药相关。
关键数值与推荐
- NFKBIE基因在3-7%的CLL患者中发生突变。
- 最常见突变为4-bp移码缺失,与白血病B细胞NF-κB激活及不良临床结局相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The NFKBIE gene, which encodes the NF-κB inhibitor IκBε, is mutated in 3-7% of patients with chronic lymphocytic leukemia (CLL). The most recurrent alteration is a 4-bp frameshift deletion associated with NF-κB activation in leukemic B cells and poor clinical outcome. To study the functional consequences of NFKBIE gene inactivation, both in vitro and in vivo, we engineered CLL B cells and CLL-prone mice to stably down-regulate NFKBIE expression and investigated its role in controlling NF-κB activity and disease expansion. We found that IκBε loss leads to NF-κB pathway activation and promotes both migration and proliferation of CLL cells in a dose-dependent manner. Importantly, NFKBIE inactivation was sufficient to induce a more rapid expansion of the CLL clone in lymphoid organs and contributed to the development of an aggressive disease with a shortened survival in both xenografts and genetically modified mice. IκBε deficiency was associated with an alteration of the MAPK pathway, also confirmed by RNA-sequencing in NFKBIE-mutated patient samples, and resistance to the BTK inhibitor ibrutinib. In summary, our work underscores the multimodal relevance of the NF-κB pathway in CLL and paves the way to translate these findings into novel therapeutic options.
引用
- Bordini J, Lenzi C, Frenquelli M, et al. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia. Leukemia. 2024. PMID: 38575671. doi:10.1038/s41375-024-02236-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。